FNY Managed Accounts’s BioLineRX BLRX Stock Holding History

FNY Managed Accounts’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$1K	Sell	3 -1	-25%	-$613	﹤0.01%	493
2017 Q4	$2K	Sell	4 -23	-85%	-$15.2K	﹤0.01%	510
2017 Q3	$17K	Buy	+27	New	+$16.8K	0.02%	368

Other funds holding BLRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

FNY Managed Accounts's BLRX Position: Q1 2018 in Review

FNY Managed Accounts reduced its BioLineRX (BLRX) stake by 25% in Q1 2018, selling an estimated $613 and leaving 3 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #493.

FNY Managed Accounts first reported a position in BLRX in Q3 2017 and has held it in 3 quarters since. The position peaked at $17K in Q3 2017. 28 funds tracked by Wall St. Rank hold BLRX as of Q1 2018.

FNY Managed Accounts held 3 shares of BioLineRX worth $1K as of Q1 2018.
FNY Managed Accounts sold 1 BioLineRX share in Q1 2018, an estimated $613.
BioLineRX made up ﹤0.01% of FNY Managed Accounts's portfolio in Q1 2018, its #493 holding.
FNY Managed Accounts first reported a position in BioLineRX in Q3 2017 and has held it in 3 quarters since.
FNY Managed Accounts's BioLineRX position peaked at $17K in Q3 2017.
28 funds tracked by Wall St. Rank held BioLineRX as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.